Document is current
Any future updates will be listed below
-
Authors
Hamid, Omid
Hassel, Jessica C https://orcid.org/0000-0001-7575-6230
Shoushtari, Alexander N https://orcid.org/0000-0002-8065-4412
Meier, Friedegund https://orcid.org/0000-0003-4340-9706
Bauer, Todd M
Salama, April K S
Kirkwood, John M
Ascierto, Paolo A https://orcid.org/0000-0002-8322-475X
Lorigan, Paul C
Mauch, Cornelia
Orloff, Marlana
Evans, Thomas R Jeffry
Holland, Chris
Edukulla, Ramakrishna
Abedin, Shaad E
Middleton, Mark R https://orcid.org/0000-0003-0167-1685
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02535078 at ClinicalTrials.govnct03070392 at ClinicalTrials.govDocuments that mention this clinical trial
Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy
https://doi.org/10.1136/jitc-2025-013246
546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
https://doi.org/10.1136/jitc-2021-sitc2021.546
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
https://doi.org/10.1136/jitc-2023-006747
nct01211262 at ClinicalTrials.govDocuments that mention this clinical trial
Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.9537
Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression.
https://doi.org/10.1200/jco.2024.42.16_suppl.9536
538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
https://doi.org/10.1136/jitc-2021-sitc2021.538
868 Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels
https://doi.org/10.1136/jitc-2021-sitc2021.868
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
https://doi.org/10.1136/jitc-2023-006747
30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial
https://doi.org/10.1136/jitc-2023-sitc2023.0030
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
619 Tebentafusp induced T and B cell epitope spread in patients with advanced melanoma
https://doi.org/10.1136/jitc-2022-sitc2022.0619
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
https://doi.org/10.1136/jitc-2023-006747
-
Funding
Funding for this research was provided by:
Immunocore Ltd. (N/A)
- License Information
